Journal
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Volume 31, Issue 2, Pages 272-278Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/ijgc-2020-002112
Keywords
BRCA1 protein; BRCA2 protein; fallopian tube neoplasms; ovarian neoplasms
Categories
Funding
- Astra Zeneca
Ask authors/readers for more resources
The British Gynecological Cancer Society and the British Association of Gynecological Pathologists established a multidisciplinary consensus group to identify optimal pathways for BRCA germline and tumor testing in ovarian cancer patients. The group explored models of consent, quality standards at pathology laboratories, and experience from cancer centers to make recommendations for implementation.
The British Gynecological Cancer Society and the British Association of Gynecological Pathologists established a multidisciplinary consensus group comprising experts in surgical gynecological oncology, medical oncology, genetics, and laboratory science, and clinical nurse specialists to identify the optimal pathways to BRCA germline and tumor testing in patients with ovarian cancer in routine clinical practice. In particular, the group explored models of consent, quality standards identified at pathology laboratories, and experience and data from pioneering cancer centers. The group liaised with representatives from ovarian cancer charities to also identify patient perspectives that would be important to implementation. Recommendations from these consensus group deliberations are presented in this manuscript.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available